Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE)
Rana R. McKay(University of San Diego), Toni K. Choueiri(Dana-Farber Cancer Institute), Xiao X. Wei(Dana-Farber Cancer Institute), Yousef Zakharia(University of Iowa Hospitals and Clinics), Lauren C. Harshman(Dana-Farber Cancer Institute), Bradley A. McGregor(Harvard University), Christos E. Kyriakopoulos(Dana-Farber Cancer Institute), Wanling Xie(Dana-Farber Cancer Institute), David A. Braun(Yale Cancer Center), Tracy L. Rose(University of North Carolina at Chapel Hill), David F. McDermott(Beth Israel Deaconess Medical Center), Walter M. Stadler(University of Maryland, Baltimore), Benjamin L. Maughan(University of Utah)
Cited by 105
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k